Jardiance first gained FDA approval in 2014 as a treatment to help lower blood sugar in adults with type 2 diabetes. Now, the drug can also be used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and cardiovascular disease.
The agency’s decision is based on results from a postmarket study showing Jardiance reduced deaths by 32 percent in patients with type 2 diabetes who are at risk of heart attack and stroke, according to a Reuters report. Patients in the study also had a 35 percent lower rate of hospitalization for heart failure.
Eli Lilly, who developed the drug through a partnership with German drugmaker Boehringer Ingelheim, can now include data from the postmarket study on the drug’s label.
More articles on supply chain:
Supply chain tip of the week: Make hospital supplies visible to help improve workflows
Apple to launch first distribution center in India: 3 things to know
Study: Cancer drugs may stay approved despite proof of inefficacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
